Feasibility analysis of pharmacy practice based on the evidence-based pharmacy model in the treatment of patients with severe pneumonia
Abstract
ABSTRACT Objective: To investigate the application of pharmacy practice based on the evidence-based pharmacy (EBP) model in the anti-infective treatment of patients with severe pneumonia. Methodology: This was a retrospective study. A total of 200 patients diagnosed with severe pneumonia caused by multidrug-resistant Gram-negative bacilli(MDR-GNB) and admitted to Baoding No.1 Central Hospital from April 2023 to March 2024 were randomly assigned to a control group(received conventional anti-infective treatment) and an experimental group(in addition to the conventional treatment, received pharmacy practice interventions based on the EBP model implemented by clinical pharmacists), with one hundred cases in each group.The two groups were compared in terms of antimicrobial drug use intensity, pre-antibiotic microbiological testing rates, clinical efficacy, adverse reaction rates, and irrational drug use. Results: The antimicrobial drug use intensity in the experimental group was significantly lower than that in the control group (P< 0.05), while the pre-antibiotic microbiological testing rate was significantly higher (P< 0.05). The antimicrobial drug costs and anti-infective treatment duration in the experimental group were lower than those in the control group (P< 0.05, respectively). The bacterial eradication and overall response in the experimental group were significantly higher than those in the control group (P< 0.05, respectively). Furthermore, adverse reaction and…
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 200 participants or records.
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.